Product Information
CLOPIDOGREL 300 MG TABLET is a generic product labeled by American Health Packaging, priced at $5.2911 per EA under NDC 68084075219. Its NADAC has been published 63 times since Mar 19, 2025.
FDA first approved this application on May 17, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
American Health PackagingNDC
68084075219
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLOPIDOGREL BISULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA076274FDA Approved
5/17/2012
TE Code
AB
On Market Since
3/28/2014
Pharmacological Classes
Price Statistics
The NADAC for CLOPIDOGREL 300 MG TABLET has been published 63 times since Mar 19, 2025, and over the history we have for it it has declined 42.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.2911 per EA |
|---|---|
| All-time high | $9.2210 (May 13, 2026) |
| All-time low | $5.2911 (Sep 23, 2026) |
| 52-week high | $9.2210 |
| 52-week low | $5.2911 |
| Median price | $9.2210 |
| Average price | $9.0962 |
| Largest weekly change | -42.6% (Sep 23, 2026) |
| Weeks tracked | 63 |
| Tracking since | Mar 19, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
American Health Packaging manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Clopidogrel Bisulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
P2Y12 Platelet Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLOPIDOGREL 300 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CLOPIDOGREL 300 MG TABLET, manufactured by American Health Packaging, is $5.2911 per EA (NDC 68084075219), effective Sep 30, 2026.
How has the price of CLOPIDOGREL 300 MG TABLET changed over time?
Over the history we have for it, the NADAC for CLOPIDOGREL 300 MG TABLET has declined 42.6%. It has been tracked across 63 weekly CMS publications since Mar 19, 2025.
What are the highest and lowest recorded NADAC prices for CLOPIDOGREL 300 MG TABLET?
Since Mar 19, 2025, the NADAC for CLOPIDOGREL 300 MG TABLET has ranged from a low of $5.2911 (Sep 23, 2026) to a high of $9.2210 (May 13, 2026), with a median of $9.2210 per EA.
Are there cheaper alternatives to CLOPIDOGREL 300 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CLOPIDOGREL 300 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures CLOPIDOGREL 300 MG TABLET?
CLOPIDOGREL 300 MG TABLET (NDC 68084075219) is labeled by American Health Packaging, and CMS classifies it as a generic product.